Showing 6661-6670 of 7643 results for "".
- Alastin Skincare Launches Trihex Transition Duo at ASDShttps://practicaldermatology.com/news/alastin-skincare-launches-trihex-transition-duo-at-asds/2458027/ALASTIN Skincare®, Inc. is launching the TriHex Transition Duo at the American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago. The TriHex Transition Duo includes a full-size Regenerating Skin Nectar for use pre- and post-procedure and a
- Penn Derm Awarded $8.6M to Study Home Versus In-Office Phototherapy Treatment for Psoriasishttps://practicaldermatology.com/news/penn-derm-awarded-86m-to-study-home-versus-in-office-phototherapy-treatment-for-psoriasis/2458030/A research team at the University of Pennsylvania will receive $8.6 million to study the effectiveness of home-based phototherapy treatments for psoriasis compared to treatments that require a visit to a doctor’s office three times a week. The Patien
- Study IDs Racial and Ethnic Disparities in Pediatric Eczema Treatmenthttps://practicaldermatology.com/news/study-ids-racial-and-ethnic-disparities-in-pediatric-eczema-treatment/2458033/White children in the US are more likely to see a doctor for treatment of eczema than black children, despite the fact that the disease is likely more severe among minorities. Research from the Perelman School of Medicine at the University of Pennsylvan
- Novan Has Guidance Meeting with FDA on SB204https://practicaldermatology.com/news/novan-has-guidance-meeting-with-fda-on-sb204/2458040/Novan, Inc. is eyeing an additional pivotal trial for its investigational treatment for acne vulgaris, SB204. The company concluded a guidance meeting with the FDA regarding SB204 in which the agency advised that an additional pivotal trial should be conducted. Given the need for the ad
- Dr. Michael H. Gold Joins AIVITA Scientific Advisory Boardhttps://practicaldermatology.com/news/dr-michael-h-gold-joins-aivita-scientific-advisory-board/2458042/Nashville dermatologist Michael H. Gold, MD, has joined AIVITA Biomedical’s Scientific Advisory Board. His addition comes as AIVITA prepares to launch its upcoming ROOT OF SKINTM line of rejuvenating skincare products. Dr. Gold,
- New Data: Aclaris' A-101 40% Safely Banishes Facial SK Lesionshttps://practicaldermatology.com/news/new-data-aclaris-a-101-40-safely-banishes-facial-sk-lesions/2458044/Good news for Aclaris. New data suggest that their drug candidate A-101 40 percent may be an appealing option to remove seborrheic keratosis (SK) lesions in highly visible areas, such as the face, with minimal risk of s
- New Label Reflects Sustained Response for Sun Pharma's Odomzo in BCChttps://practicaldermatology.com/news/new-label-reflects-sustained-response-for-sun-pharmas-odomzo-in-bcc/2458045/Sun Pharma’s new Odomzo® (Sonidegib) label incorporates long-term data showing sustained duration of response of 26 months in treatment of locally advanced basal cell carcinoma. Odomzo® is an oral hedgehog inhibitor indicated for t
- Eva Genel Named Director of Research and Development, Skincare at Silk Therapeuticshttps://practicaldermatology.com/news/eva-genel-named-director-of-research-and-development-skincare-at-silk-therapeutics/2458047/Eva Genel is the new Director of Research and Development, Skincare at Silk Therapeutics Inc., a specialty biomaterials company. In this new role, Genel's key responsibilities include designing and assessing clean, skincare formulations, o
- U.K Survey Reveals Eczema Treatment Knowledge Gaphttps://practicaldermatology.com/news/survey-reveals-eczema-treatment-knowledge-gap/2458049/Two thirds of UK eczema patients don’t understand that bacteria play a crucial role in their condition despite studies showing that Staphylococcus aureus is present on the skin in of more than 70 percent of patients, according to research from
- Lilly's Baricitinib Performs Well in Phase 2 AD Studyhttps://practicaldermatology.com/news/lillys-baricitinib-performs-well-in-phase-2-ad-study/2458052/Lilly’s experimental JAK inhibitor Baricitinib in combination with a mid-potency topical corticosteroid (TCS) significantly improved the signs and symptoms of moderate-to-severe atopic dermatitis (AD) compared to TCS alone, with improvements seen as earl